SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Swell

Swell is gaining attention as community members highlight its low market cap and potential for significant growth, particularly with increased volume and its listing on Coinbase. Some users are drawing comparisons to other cryptocurrencies, suggesting Swell could experience a similar surge, while others discuss its liquid staking protocol and upcoming L2 Swell chain. However, some caution against potential risks, pointing to past performance and developer activity.

Zcash is a decentralized and open-source cryptocurrency that offers privacy and selective transparency of transactions. Zcash payments are published on a public blockchain, but the sender, recipient, and amount of a transaction remain private.  Zcash is based on peer-reviewed cryptographic research, and built by a security-specialized engineering team on an open source platform based on Bitcoin Core's battle-tested codebase. Our improvement over Bitcoin is the addition of privacy. Zcash uses advanced cryptographic techniques, namely zero-knowledge proofs, to guarantee the validity of transactions without revealing additional information about them.  How Zcash works  Zcash encrypts the contents of shielded transactions. Since the payment information is encrypted, the protocol uses a novel cryptographic method to verify their validity.  Zcash uses a zero-knowledge proof construction called a zk-SNARK, developed by our team of experienced cryptographers based on recent breakthroughs in cryptography. These constructions allow the network to maintain a secure ledger of balances without disclosing the parties or amounts involved. Instead of publicly demonstrating spend-authority and transaction values, the transaction metadata is encrypted and zk-SNARKs are used to prove that nobody is cheating or stealing.  Zcash also enables users to send public payments which work similarly to Bitcoin. With the support for both shielded and transparent addresses, users can choose to send Zcash privately or publicly. Zcash payments sent from a shielded address to a transparent address reveal the received balance, while payments from a transparent address to a shielded address protect the receiving value.   Check out CoinBureau for guide on What is ZCash.

Zcash

Zcash is trending as community members discuss its recent surge and potential as a privacy-focused alternative to Bitcoin. Bullish sentiment is fueled by speculation about limited supply, increased adoption of shielded addresses, and comparisons to Bitcoin's early days. Concerns about volatility and potential pullbacks are also being weighed as the crypto community assesses ZEC's future.

COTI is a fast and light confidentiality layer on Ethereum. Powered by the breakthrough cryptographic protocol Garbled Circuits and secured by Ethereum, COTI introduces the most advanced and compliant solution for data protection on the public blockchain. Paving the way for the next wave of Web3 innovation and adoption, COTI unlocks a whole new world of use cases, including confidential transactions, Artificial Intelligence, DeFi, decentralized identification, and more.

COTI

COTI is trending as community members highlight its potential within the privacy coin sector, drawing comparisons to established projects like Zcash and Ethereum.  Enthusiasts are actively discussing COTI's underlying technology and anticipating potential catalysts, including the upcoming mainnet launch. There's also broader conversation around AI integration, which has driven chatter surrounding this project.

Internet Computer (IC) is the world’s first blockchain that is capable of running at web speed at unrestrictive capacities. Built by the DFINITY Foundation, IC aims to recreate the web by supporting smart contract development at scale and changing the way people can interact using web services. Internet Computer aims to extend the public internet, so that it can be the world’s computing platform, in a decentralized manner. Internet Computer sets to revolutionalize the design of the crypto economy, with an aim to overhaul traditional software services.   The project was founded in October 2016 by Dominic WIllams and have raised a total of $121 million from investors such as Adreessen Horowitz, Polychain Capital, Multicoin Capital and such. On May 10, 2021, DFINITY launched the Internet Computer into the public domain, marking it a major milestone for ICP as it means the internet now functions as a decentralised global computer. This is marked by the release of all of the Internet Computer’s source code into the public domain, as well as ICP utility token that allows tens of thousands of community members to govern the Internet Computer network.  ICP is Internet Computer's native token. It plays three prominent roles:  1. Network Governance: Users that participate in the governance will be rewarded with ICPI 2. Production of Cycles for Compute: ICP can be converted into cycles where it is used as the transaction fee to access the network. Cycles are burned after used. 3. Rewarding Users: ICP is used as the rewards to incentivize users to participate in the network such as securing the network.

Internet Computer

ICP is trending as the community discusses its potential as a decentralized compute platform and its integration with AI, particularly after the launch of Caffeine AI. Bullish sentiment is fueled by the belief that ICP addresses key limitations in the blockchain space, although some caution against a potential pullback. Discussions also revolve around comparing ICP to other trending cryptocurrencies, such as ZEC.

What Is Tezos (XTZ)?   Tezos is a high-performing blockchain and open-source platform for assets and applications, with a strong focus on code security, on-chain governance, and decentralization. Tezos 2.0, the upcoming step in the evolution of Tezos, aims to improve scalability (via layer 2s), composability, and to implement support to mainstream programming languages (like Javascript, Typescript, Python, and many others).   Initially built with formal verification in mind, the Tezos protocol enables builders to avoid bugs when developing smart contracts, making it particularly suited to applications that require a high degree of security and certainty.   Tezos’ LPoS (Liquid Proof-of-Stake) consensus mechanism enables any stakeholder to take part, directly or by delegation, in the consensus process, and to be rewarded for securing the network. Rather uniquely, Tezos’ on-chain governance system also enables stakeholders to create and vote on protocol upgrade proposals. This pioneering system allows the protocol to self-amend and upgrade itself without leading to a split (or fork) in the blockchain, empowering the community without slowing down innovation.   First proposed in 2014 and launched in 2018, the Tezos Mainnet has a proven track record of running uninterrupted ever since, having earned a strong reputation for technical excellence and a supportive community.    Who Are the Founders of Tezos? Tezos was conceived by Arthur and Kathleen Breitman in a 2014 white paper under the pseudonym L.M. Goodman in a nod to Satoshi Nakamoto, referencing a journalist who had misidentified the creator of Bitcoin.   In a previous paper, the Breitmans had argued that Bitcoin's biggest shortcomings were the lack of a governance process that invited contributions from its community of users, cost and centralization issues raised by its proof-of-work system, the limited expressiveness of its programming language which didn’t allow for smart contracts, and security

Tezos

Tezos is trending amid volatile price action, sparking heated debates about potential pumps and dumps. The community is sharply divided, with some labeling holders as "suckers" and anticipating further drops, while others express optimism and highlight staking rewards. Discussions also involve comparisons to other cryptocurrencies and speculation about future catalysts like FED rate cuts.

BtcUSD is a completely decentralized stablecoin issued and managed by BTCFi, a platform where users can deposit Bitcoin of various formats to use as collaterals. BtcUSD offers Bitcoin holders the opportunity to generate additional yields with their Bitcoin positions through DeFi usage.

Bitcoin USD (BTCFi)

Bitcoin is seeing active discussion regarding potential resistance and support levels as the price consolidates, with some traders anticipating a volatility spike. Community members are weighing bullish and bearish scenarios, referencing Elliott Wave analysis and Fibonacci levels to predict future price movements. Others point to increasing institutional ownership and historical patterns to support a long-term bullish outlook.

GALA is designed to power the Gala Games ecosystem to support gaming re-imagined to benefit creators and players, alike.

Gala Games

GALA is trending amid general market optimism, with community members discussing potential price targets and accumulating more coins. Upcoming catalysts related to GalaChain development, game integrations, and expansion into film/music are also circulating. Some users express frustration with the token's performance compared to other cryptocurrencies, while others remain bullish on its long-term potential.

Basic Attention Token (BAT) is an open-source, decentralized ad exchange platform built on Ethereum platform. Basic Attention Token held an initial coin offering on May 31, 2017 for its eponymous ERC-20 utility token, raising approximately $35M USD at the time in less than 30 seconds. The Basic Attention Token aims to fix digital advertising, which is broken, fraudulent and opaque.   Basic Attention Token work by having advertisers pay BAT to website publishers for the attention of users. The BAT token is designed to correctly value and price user attention within the platform. The Basic Attention Token comprises various components, including attention measurement systems, analytics dashboards and machine learning algorithms. Integration of BAT into a given host application involves implementing BAT Ads, a system that matches and displays ads to users based on locally stored data. Ad targeting is performed wholly on-device, removing the need for third-party tracking. BAT is focused on the Brave browser. Brave is an open-source, privacy-centered browser designed to block trackers and malware. It utilizes blockchain technology to anonymously and securely track user attention, which translates into rewards for publishers.  A user's attention, meaning his or her focused mental engagement on digital content like advertisements, is logged through Brave. The makers of BAT indicate that the user's private data and tracking information is stored only on the user's device, ensuring that it is anonymous and private.  Created back in 2016, the Basic Attention Token has one of the biggest names behind it, that of Brendan Eich, the creator of JavaScript and the legendary co-founder of Mozilla. Other noteworthy team members include Brian Bondy, lead developer and co-founder of Brave and Scott Locklin, senior engineer, and co-founder of Kerf Software."  Basic Attention Token is created by the team that built the Brave browser, an open-source, privacy-focused browser that blocks ads and trackers. The browser measures user attention and rewards publishers for users attention.   Use the Brave browser to protect your privacy and support CoinGecko at the same time: https://brave.com/coi600

Basic Attention Token

Basic Attention Token is trending as community members discuss its real-world utility through the Brave Browser and potential for significant growth. Discussions also highlight positive user statistics and growing adoption of the browser's privacy-focused features. Some traders are pointing to recent chart activity, suggesting a potential breakout is on the horizon.

Karyopharm Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. The company was founded by Joseph Araujo, Ronald A. DePinho, Pamela A, Silver, Giulio Draetta, Michael G. Kauffman, and Sharon Shacham on December 22, 2008, and is headquartered in Newton, MA.

Karyopharm Therapeutics Inc

KPTI is trending due to frustration and criticism surrounding its CEO Richard Paulson, with shareholders expressing concerns about value destruction and mismanagement; some are calling for his removal. Despite recent positive analyst ratings and potential catalysts, community sentiment remains largely negative, focusing on the company's financial performance and leadership. The discussion also includes concerns about potential reverse stock splits and the company's future direction.

Our mission is to democratize real estate investment by providing accessible education and innovative tools. Through our learn-to-earn platform and tokenization hub, we're bridging the gap between traditional real estate and the future of decentralized finance. GCoin is the fuel to our ecosystem that powers our platform and gives us the ability and the community to spread this information that has been locked away by the wealthy.

GCoin

GCoin ($GC) is trending as the community focuses on its real-world asset (RWA) utility, particularly its connection to tokenized real estate through Gilmore Estates. Discussions highlight passive income opportunities for NFT holders, recent listings on exchanges like Uniswap, and the potential for long-term growth. Community members emphasize $GC's unique position in bridging cryptocurrency with tangible assets, creating demand and real-world value.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Y Intercept Hong Kong Ltd Acquires New Position in Disc Medicine, Inc. $IRON

Y Intercept Hong Kong Ltd bought a new position in Disc Medicine, Inc. (NASDAQ:IRON - Free Report) in the 2nd quarter, according to the company in its most recent filing with the Securities and...

What Makes Disc Medicine, Inc. (IRON) a Strong Momentum Stock: Buy Now?

Does Disc Medicine, Inc. (IRON) have what it takes to be a top stock pick for momentum investors? Let's find out.

Does Disc Medicine, Inc. (IRON) Have the Potential to Rally 26.29% as Wall Street Analysts Expect?

The consensus price target hints at a 26.3% upside potential for Disc Medicine, Inc. (IRON). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Shares of Revolution Medicines, Disc Medicine, and Regeneron Pharmaceuticals rose in after-hours trading on Thursday after the U.S. Food and Drug Administration (FDA) announced the first group of drugs selected for expedited review under its new National Priority Voucher pilot program.In after-hours trading on Thursday,&nbsp;<a href="https://stocktwits.com/symbol/RVMD">Revolution Medicines</a> jumped 9%,&nbsp;<a href="https://stocktwits.com/symbol/IRON">Disc Medicine</a> surged 17%, and&nbsp;<a href="https://stocktwits.com/symbol/REGN">Regeneron Pharmaceuticals</a> edged up 0.1%.FDA Names 9 Drugs For Accelerated ReviewThe FDA said nine products have been chosen for the fast-track review process, which shortens decision timelines from the usual 10–12 months to just one or two months once a complete application is filed.The selected drugs include Merck KGaA’s fertility treatment Pergoveris, Sanofi’s Type 1 diabetes therapy teplizumab, Regeneron’s gene therapy DB-OTO for congenital deafness, and ketamine for domestic manufacturing of a general anesthetic.&nbsp;Also on the list are Revolution Medicines’ RMC-6236 for pancreatic cancer, Disc Medicine’s bitopertin for porphyria, Achieve Life Sciences’ cytisinicline for nicotine vaping addiction, Dompe’s cenegermin-bkbj for blindness, and Augmentin XR for domestic manufacturing of a common antibiotic.FDA Commissioner Highlights Expedited Review EffortFDA Commissioner Marty Makary said the initiative could shorten FDA decision times from a year to "a matter of weeks” by moving promising or high-impact therapies to the front of the review line.Makary said some of the drugs selected for vouchers, including one that uses ketamine as a general anesthetic, will be manufactured in the United States. He described Regeneron’s DB-OTO, a gene therapy for congenital deafness, as “an exciting treatment,” noting that “some of these kids got normal hearing from this amazing treatment.”He added that this is just the first round of vouchers, with additional selections expected in the coming weeks.How Stocktwits Traders Reacted To FDA’s Fast-Track ListOn Stocktwits, retail sentiment toward Revolution Medicines was ‘extremely bullish’ with ‘extremely high’ message volume, while Disc Medicine saw ‘neutral’ sentiment amid similarly ‘extremely high’ activity, and Regeneron registered ‘neutral’ sentiment with ‘normal’ engagement levels.One&nbsp; user said they expect Regeneron shares to climb steadily, projecting the stock could reach the $800-$900 range within two years.&nbsp;<stembedurl>https://stocktwits.com/Iwannagofast1/message/632653980</stembedurl>Another bullish trader suggested Revolution Medicines could be an attractive takeover candidate, potentially fetching twice its current value.<stembedurl>https://stocktwits.com/ChessGM/message/632555600</stembedurl>So far this year, Revolution Medicines shares have gained 14%, Disc Medicine is up 17%, while Regeneron has declined 20%.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the FDA (United States Food and Drug Administration) logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Revolution Medicines, Disc Medicine, Regeneron Stocks Jump After-Hours As FDA Fast-Tracks 9 Drugs Under New Review Program

The FDA’s new National Priority Voucher pilot helps with faster drug reviews, cutting timelines from nearly a year to weeks.

Equity

Raymond James bullish on biotech firms on favorable valuation

Investing.com -- Raymond James started coverage on biotechnology companies, rating Avidity Biosciences and Disc Medicine at Strong Buy and assigning Outperform ratings to Dyne Therapeutics, Tectonic Therapeutic, and Wave Life Sciences (NASDAQ:WVE), pointing to a sector-wide opportunity amid “suppressed valuations.”

Disc Medicine (NASDAQ:IRON) Given "Outperform" Rating at Wedbush

Wedbush reaffirmed their outperform rating on shares of Disc Medicine (NASDAQ:IRON - Free Report) in a report issued on Monday morning, RTT News reports. Wedbush currently has a $43.00 price...

FY2024 Earnings Estimate for Disc Medicine, Inc. Issued By Wedbush (NASDAQ:IRON)

Disc Medicine, Inc. (NASDAQ:IRON - Free Report) - Wedbush boosted their FY2024 earnings per share (EPS) estimates for Disc Medicine in a report released on Monday, April 1st. Wedbush analyst D...

Leerink Partnrs Comments on Disc Medicine, Inc.'s Q2 2024 Earnings (NASDAQ:IRON)

Disc Medicine, Inc. (NASDAQ:IRON - Free Report) - Stock analysts at Leerink Partnrs reduced their Q2 2024 earnings per share estimates for shares of Disc Medicine in a report issued on Monday, April...

Raymond James Reiterates "Outperform" Rating for Disc Medicine (NASDAQ:IRON)

Disc Medicine (NASDAQ:IRON - Get Free Report)s stock had its "outperform" rating reaffirmed by analysts at Raymond James in a report issued on Monday, Marketbeat Ratings reports. They...

Analysts Offer Insights on Healthcare Companies: Assembly Biosciences (ASMB), Natera (NTRA) and Disc Medicine (IRON)

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Assembly Biosciences (ASMB Research Report), Nater...

Disc Medicine, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of treatments for hematologic diseases. It assembles a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. The company was founded in October 2017 and is headquartered in Watertown, MA.

Disc Medicine Inc

$ASTS

$RKLB

$BBAI

$NBIS

Which earnings release are you most excited for the week of Nov. 10? 
 
Drop a comment for others.

IRON
Disc Medicine Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest IRON News

IRONDisc Medicine Inc